Nanoparticles for drug delivery to the lungs

Patton, 1996, Mechanisms of macromolecule absorption by the lungs, Adv. Drug. Deliv. Rev., 19, 3, 10.1016/0169-409X(95)00113-L Sermet-Gaudelus, 2002, Nebulized antibiotics in cystic fibrosis, Pediatr. Drugs, 4, 455, 10.2165/00128072-200204070-00004 Patton, 2004, The lungs as a portal of entry for systemic drug delivery, Proc. Am. Thorac. Soc., 1, 338, 10.1513/pats.200409-049TA Patton, 2007, Inhaling medicines: delivering drugs to the body through the lungs, Nat. Rev. Drug Discov., 6, 67, 10.1038/nrd2153 Hamman, 2005, Oral delivery of peptide drugs: Barriers and developments, BioDrugs, 19, 165, 10.2165/00063030-200519030-00003 Chellat, 2005, Therapeutic potential of nanoparticulate systems for macrophage targeting, Biomaterials, 26, 7260, 10.1016/j.biomaterials.2005.05.044 1999 Weibel, 1962, Architecture of the human lung: Use of quantitative methods establishes fundamental relations between size and number of lung structures, Science, 137, 577, 10.1126/science.137.3530.577 Weibel, 1973, Morphological basis of alveolar-capillary gas exchange, Physiol. Rev., 53, 419, 10.1152/physrev.1973.53.2.419 Gehr, 1978, The normal human lung: ultrastructure and morphometric estimation of diffusion capacity, Respir. Physiol., 32, 121, 10.1016/0034-5687(78)90104-4 Stone, 1992, Allometric relationships of cell numbers and size in the mammalian lung, Am. J. Respir. Cell Mol. Biol., 6, 235, 10.1165/ajrcmb/6.2.235 Fels, 1986, The alveolar macrophage, J. Appl. Physiol., 60, 353, 10.1152/jappl.1986.60.2.353 Edwards, 1998, Recent advances in pulmonary drug delivery using large, porous inhaled particles, J. Appl. Physiol., 85, 379, 10.1152/jappl.1998.85.2.379 Oberdorster, 2005, Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles, Environ. Health Perspect., 113, 823, 10.1289/ehp.7339 de Heer, 2005, Dendritic cell subsets and immune regulation in the lung, Semin. Immunol., 17, 295, 10.1016/j.smim.2005.05.002 Heyder, 1986, Deposition of particles in the human respiratory tract in the size range 0.005–15μm, J. Aerosol Sci., 17, 811, 10.1016/0021-8502(86)90035-2 Crompton, 2006, A brief history of inhaled asthma therapy over the last fifty years, Prim. Care Respir. J., 15, 326, 10.1016/j.pcrj.2006.09.002 Pauwels, 1997, Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers, Eur. Respir. J., 10, 2127, 10.1183/09031936.97.10092127 Busse, 2000, Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma, J. Allergy Clin. Immunol., 106, 1209, 10.1067/mai.2000.111582 Atkins, 2005, Dry powder inhalers: an overview, Respir. Care, 50, 1304 Edwards, 1997, Large porous particles for pulmonary drug delivery, Science, 276, 1868, 10.1126/science.276.5320.1868 Dunbar, 2002, In vitro and in vivo dose delivery characteristics of large porous particles for inhalation, Int. J. Pharm., 245, 179, 10.1016/S0378-5173(02)00349-6 Vanbever, 1999, Formulation and physical characterization of large porous particles for inhalation, Pharm. Res., 16, 1735, 10.1023/A:1018910200420 Bosquillon, 2001, Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance, J. Control. Release, 70, 329, 10.1016/S0168-3659(00)00362-X Gupta, 2000, Physical characterization of large porous particles for inhalation, Pharm. Res., 17, 1437, 10.1023/A:1007563309508 Kreuter, 2007, Nanoparticles-a historical perspective, Int. J. Pharm., 331, 1, 10.1016/j.ijpharm.2006.10.021 Kreuter, 1991, Nanoparticle-based drug delivery systems, J. Control. Release, 16, 169, 10.1016/0168-3659(91)90040-K Anderson, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 28, 5, 10.1016/S0169-409X(97)00048-3 Panyam, 2003, Polymer degradation and in vitro release of a model protein from poly(dl-lactide-co-glycolide) nano- and microparticles, J. Control. Release, 92, 173, 10.1016/S0168-3659(03)00328-6 Birnbaum, 2000, Optimization of preparation techniques for poly(lactic acid-co-glycolic acid) nanoparticles, J. Nanoparticle Res., 2, 173, 10.1023/A:1010038908767 Horn, 2001, Organic nanoparticles in the aqueous phase - theory, experiment, and use, Angew. Chem. Int. Ed. Engl., 40, 4330, 10.1002/1521-3773(20011203)40:23<4330::AID-ANIE4330>3.0.CO;2-W Astete, 2006, Synthesis and characterization of PLGA nanoparticles, J. Biomater. Sci. Polym. Ed., 17, 247, 10.1163/156856206775997322 Brannon-Peppas, 2004, Nanoparticle and targeted systems for cancer therapy, Adv. Drug. Deliv. Rev., 56, 1649, 10.1016/j.addr.2004.02.014 Pandey, 2005, Antitubercular inhaled therapy: opportunities, progress and challenges, J. Antimicrob. Chemother., 55, 430, 10.1093/jac/dki027 Gelperina, 2005, The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis, Am. J. Respir. Crit. Care Med., 172, 1487, 10.1164/rccm.200504-613PP Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283 Soppimath, 2001, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release, 70, 1, 10.1016/S0168-3659(00)00339-4 Hans, 2002, Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater. Sci., 6, 319, 10.1016/S1359-0286(02)00117-1 Panyam, 2003, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv. Drug Deliv. Rev., 55, 329, 10.1016/S0169-409X(02)00228-4 Kawashima, 1999, Pulmonary delivery of insulin with nebulized -lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect, J. Control. Release, 62, 279, 10.1016/S0168-3659(99)00048-6 Zhang, 2001, Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats, Int. J. Pharm., 218, 75, 10.1016/S0378-5173(01)00614-7 Yamamoto, 2005, Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions, J. Control. Release, 102, 373, 10.1016/j.jconrel.2004.10.010 Vaughn, 2006, Single dose and multiple dose studies of itraconazole nanoparticles, Eur. J. Pharm. Biopharm., 63, 95, 10.1016/j.ejpb.2006.01.006 Pandey, 2003, Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis, J. Antimicrob. Chemother., 52, 981, 10.1093/jac/dkg477 Sharma, 2004, Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis, J. Antimicrob. Chemother., 54, 761, 10.1093/jac/dkh411 Zahoor, 2005, Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis, Int. J. Antimicrob. Agents, 26, 298, 10.1016/j.ijantimicag.2005.07.012 Dailey, 2003, Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features, J. Control. Release, 86, 131, 10.1016/S0168-3659(02)00370-X Wendorf, 2006, A practical approach to the use of nanoparticles for vaccine delivery, J. Pharm. Sci., 95, 2738, 10.1002/jps.20728 Saez, 2000, Freeze-drying of polycaprolactone and poly(-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs, Eur. J. Pharm. Biopharm., 50, 379, 10.1016/S0939-6411(00)00125-9 Tsapis, 2002, Trojan particles: large porous carriers of nanoparticles for drug delivery, Proc. Natl. Acad. Sci. U. S. A., 99, 12001, 10.1073/pnas.182233999 Hadinoto, 2006, Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs, Ind. Eng. Chem. Res., 45, 3697, 10.1021/ie0513191 Hadinoto, 2007, Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids, Int. J. Pharm., 333, 187, 10.1016/j.ijpharm.2006.10.009 Jones, 2002, The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages, Int. J. Pharm., 236, 65, 10.1016/S0378-5173(02)00016-9 Sham, 2004, Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung, Int. J. Pharm., 269, 457, 10.1016/j.ijpharm.2003.09.041 Ely, 2007, Effervescent dry powder for respiratory drug delivery, Eur. J. Pharm. Biopharm., 65, 346, 10.1016/j.ejpb.2006.10.021 Hadinoto, 2007, Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery, Int. J. Pharm., 341, 195, 10.1016/j.ijpharm.2007.03.035 Cook, 2005, Novel sustained release microspheres for pulmonary drug delivery, J. Control. Release, 104, 79, 10.1016/j.jconrel.2005.01.003 Azarmi, 2006, Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles, Int. J. Pharm., 319, 155, 10.1016/j.ijpharm.2006.03.052 Grenha, 2005, Microencapsulated chitosan nanoparticles for lung protein delivery, Eur. J. Pharm. Sci., 25, 427, 10.1016/j.ejps.2005.04.009 Grenha, 2007, Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro, Eur. J. Pharm. Sci., 31, 73, 10.1016/j.ejps.2007.02.008 Mossman, 2007, Mechanisms of action of inhaled fibers, particles and nanoparticles in lung and cardiovascular diseases, Part. Fibre Toxicol., 4, 4, 10.1186/1743-8977-4-4 Oberdorster, 2002, Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats, J. Toxicol. Environ. Health A, 65, 1531, 10.1080/00984100290071658 Kreyling, 2002, Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low, J. Toxicol. Environ. Health A, 65, 1513, 10.1080/00984100290071649 Elder, 2006, Translocation of inhaled ultrafine manganese oxide particles to the central nervous system, Environ. Health Perspect., 114, 1172, 10.1289/ehp.9030 Warheit, 2007, Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: Differential responses related to surface properties, Toxicology, 230, 90, 10.1016/j.tox.2006.11.002 Hoet, 2004, Nanoparticles - known and unknown health risks, J. Nanobiotechnology, 2, 12, 10.1186/1477-3155-2-12 Borm, 2004, Toxicological hazards of inhaled nanoparticles–potential implications for drug delivery, J. Nanosci. Nanotechnol., 4, 521, 10.1166/jnn.2004.081 Dailey, 2006, Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung, Toxicol. Appl. Pharmacol., 215, 100, 10.1016/j.taap.2006.01.016